Lidereau et al.[8] found they could improve the likelihood of detecting BRCA1 mutations in a series of patients with invasive breast cancer, under 35 years of age, when they selected patients with estrogen receptor (ER) negative, high grade tumors (37%). Here, ESR1 is linked to invasive breast carcinoma.